PD-1/PD-L1抑制剂致骨髓抑制不良反应文献分析

A Quantitative Analysis of the Literature on Bone Marrow Suppression Induced by PD-1/PD-L1 Drugs

本文在PubMed、中国知网、万方医学数据库中,对PD-1/PD-L1类药物引起骨髓抑制的个案报道进行系统检索,共得文献55篇。按照入选标准/剔除标准筛选纳入20篇(22例),其中男性14例(占63.6%).使用PD-1/PD-L1抑制剂1周期后发生骨髓抑制12例(占54.55%),17例为Ⅳ级反应(占77.3%),16例表现为血小板减少症(占72.73%),2例表现为全血细胞减少症(占9.09%)。为临床了解PD-1/PD-L1抑制剂引起骨髓抑制发生特点、制定监护计划及处理该类不良反应提供依据。

PubMed, CNKI and Wan-fang medical databases were systematically searched for case reports of myelosuppression induced by PD-1/PD-L1 drugs. A total of 55 literatures were obtained and 20(22 cases) were included for quantitative analysis. Among them, 14 cases(63.6%) were male, 11 cases(50%) had myelosuppression after using PD-1/PD-L1 inhibitors for 1 cycle, 17 cases(77.3%) were grade Ⅳ reaction, 16 cases(72.73%) were thrombocytopenia, 2 cases(9.09%) were pancytopenia. We provided a basis for medical staff to understand the characteristics of bone marrow suppression induced by PD-1/PD-L1 drugs, as well as its monitoring and treatment.